Companies
Willow Biosciences
Biosynthetic CBGA/CBG, API licensing with Laurus Labs — Engineered prenyltransferase (NphB quadruple mutant).
- Country
- Canada
biosynthesis
cbg
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $1.64 million raised through a brokered private placement in June 2024 | newswire.ca · stocktitan.net |
| Funding | $4.0 million in guaranteed research and development payments in year one of the Laurus Labs partnership | newsfile.futunn.com · newswire.ca · proactiveinvestors.com · stocktitan.net |
| Capacity | contracted manufacturing through multiple CMOs including fermentation capacity; exact volume capacity not specified | newswire.ca · sedarplus.ca |
| Certification | contract manufacturing partners hold necessary certifications for food, nutritional, and pharmaceutical markets | newswire.ca |
| Regulatory approval | FutureGrown CBG successfully completed toxicological assessments for GRAS determination in the United States; prior regulatory licenses for cannabinoid research with DEA and Health Canada were foregone | newswire.ca · sedarplus.ca |
| Production site | research facility in Sunnyvale, California (approx. 16,000 sq ft); production utilizes contract manufacturing organizations (CMOs) | sedarplus.ca |
| Headcount | 19 total employees as of most recent reporting (14 science/technical staff in Sunnyvale, 4 in Calgary, 1 in Sunnyvale) | sedarplus.ca |
| Revenue | $4.66 million in 2024 revenue; $1.0 million in Q2 2024 revenue | newsfile.futunn.com · newswire.ca · stocktitan.net |
Independent sources: newsfile.futunn.com · newswire.ca · proactiveinvestors.com · sedarplus.ca · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic cannabinoids (CBD & THC) | specialty-fine-chem | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.